Table 3 Cardiac monitoring among 80 childhood and young adult cancer survivors with low left ventricular ejection fraction
Monitoring | N (%) | LVEF 50–54.9% N = 38 (47.5%) | LVEF 41–49.9% N = 18 (25.0%) | LVEF < 41% N = 24 (30.0%) | P-valuea |
|---|---|---|---|---|---|
Cardiology referral | 56 (70.0) | 20 (52.6) | 14 (77.8) | 22 (91.7) | 0.003 |
Additional testing | |||||
Any test | 77 (96.3) | 38 (100.0) | 16 (88.9) | 23 (95.8) | 0.123 |
Electrocardiogram | 71 (88.8) | 35 (92.1) | 14 (77.8) | 22 (91.7) | 0.246 |
Holter monitor | 10 (12.5) | 4 (10.5) | 1 (5.6) | 5 (20.8) | 0.293 |
Echocardiogram stress test | 26 (32.5) | 10 (26.3) | 8 (44.4) | 8 (33.3) | 0.398 |
Nuclear stress test | 5 (6.3) | 0 (0.0) | 1 (5.6) | 4 (16.7) | 0.030 |
Pharmacological nuclear stress test | 4 (5.0) | 1 (2.6) | 2 (11.1) | 1 (4.2) | 0.387 |
MUGA scan | 4 (5.0) | 0 (0.0) | 3 (16.7) | 1 (4.2) | 0.027 |
Cardiac MRI | 18 (22.5) | 9 (23.7) | 4 (22.2) | 5 (20.8) | 0.966 |
Angiogram | 22 (27.5) | 4 (10.5) | 7 (38.9) | 11 (45.8) | 0.005 |
Echocardiogram follow-up interval | < 0.001 | ||||
< 1 year | 6 (7.5) | 0 (0.0) | 1 (5.6) | 5 (20.8) | |
1 year | 62 (77.5) | 27 (71.1) | 17 (94.4) | 18 (75.0) | |
> 1 year | 12 (15.0) | 11 (28.9) | 0 (0.0) | 1 (4.2) | |